These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25867072)

  • 21. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
    Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
    Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylation dynamics of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) is discordant with its potential to interact with eukaryotic initiation factor 4E (eIF4E).
    Showkat M; Beigh MA; Bhat BB; Batool A; Andrabi KI
    Cell Signal; 2014 Oct; 26(10):2117-21. PubMed ID: 24975846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.
    Elia A; Henry-Grant R; Adiseshiah C; Marboeuf C; Buckley RJ; Clemens MJ; Mudan S; Pyronnet S
    Cell Death Dis; 2017 Dec; 8(12):3204. PubMed ID: 29233971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
    Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
    Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.
    Kouhara J; Yoshida T; Nakata S; Horinaka M; Wakada M; Ueda Y; Yamagishi H; Sakai T
    Int J Oncol; 2007 Mar; 30(3):679-87. PubMed ID: 17273769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
    Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
    Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
    Moon DO; Asami Y; Long H; Jang JH; Bae EY; Kim BY; Choi YH; Kang CH; Ahn JS; Kim GY
    Toxicol In Vitro; 2013 Feb; 27(1):257-63. PubMed ID: 22982206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.
    Grosso S; Pesce E; Brina D; Beugnet A; Loreni F; Biffo S
    PLoS One; 2011; 6(12):e29136. PubMed ID: 22216185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.
    Yan J; Zhou H; Kong L; Zhang J; Zhao Q; Li Y
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):799-808. PubMed ID: 23934262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.
    Li T; Xu XH; Guo X; Yuan T; Tang ZH; Jiang XM; Xu YL; Zhang LL; Chen X; Zhu H; Shi JJ; Lu JJ
    Biochem Pharmacol; 2020 May; 175():113921. PubMed ID: 32201213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Med Oncol; 2014 Jan; 31(1):792. PubMed ID: 24307346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.
    Zhou X; Wang Y; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q
    J Hepatol; 2014 Oct; 61(4):746-54. PubMed ID: 24859454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.